SG10201912768YA - Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder - Google Patents
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorderInfo
- Publication number
- SG10201912768YA SG10201912768YA SG10201912768YA SG10201912768YA SG10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA
- Authority
- SG
- Singapore
- Prior art keywords
- prophylaxis
- treatment
- blood coagulation
- von willebrand
- willebrand factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16198497 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912768YA true SG10201912768YA (en) | 2020-02-27 |
Family
ID=57389201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912768YA SG10201912768YA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| SG11201903954WA SG11201903954WA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903954WA SG11201903954WA (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11890327B2 (en) |
| EP (1) | EP3538134B1 (en) |
| JP (1) | JP2020504082A (en) |
| KR (1) | KR20190073576A (en) |
| CN (1) | CN110381986B (en) |
| AU (1) | AU2017358865A1 (en) |
| CA (1) | CA3043397A1 (en) |
| DK (1) | DK3538134T3 (en) |
| ES (1) | ES2908008T3 (en) |
| SG (2) | SG10201912768YA (en) |
| TW (1) | TW201828974A (en) |
| WO (1) | WO2018087271A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021523878A (en) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | How to treat hemophilia A |
| KR20220029733A (en) * | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII |
| JP2023500953A (en) | 2019-11-11 | 2023-01-11 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Polypeptides for inducing tolerance to factor VIII |
| KR102647642B1 (en) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | Peptides having blood coagulation activity and use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| EP1621206A1 (en) | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403764B (en) * | 1996-03-15 | 1998-05-25 | Immuno Ag | STABLE FACTOR VIII / VWF COMPLEX |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| PT1079805E (en) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | PHARMACEUTICAL COMPOSITION UNDERSTANDING FACTOR VIII AND NEUTRAL LIPOSOMES |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| CA2434097A1 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| US7205278B2 (en) | 2001-06-14 | 2007-04-17 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| DK1497330T3 (en) | 2002-04-29 | 2010-06-14 | Sanquin Bloedvoorziening | Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CN102139114A (en) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | Polymer factor VIII moiety conjugates |
| ATE497783T1 (en) | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | CLOTTING FACTOR VII-FC CHIMERIC PROTEINS FOR THE TREATMENT OF HEMOSTATIC DISEASES |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1641823E (en) | 2003-06-12 | 2011-11-08 | Lilly Co Eli | Glp-1 analog fusion proteins |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| PT2371856T (en) | 2004-11-12 | 2022-08-12 | Bayer Healthcare Llc | Site-directed modification of fviii |
| EP1835938B1 (en) | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| JP2008537680A (en) | 2005-04-14 | 2008-09-25 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Modified coagulation factor VIII and derivatives thereof with increased stability |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7683158B2 (en) | 2006-03-31 | 2010-03-23 | Baxter International Inc. | Pegylated factor VIII |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| CA2673459C (en) | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
| JP2010529155A (en) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Use of VWF-stabilized FVIII and non-FVIII VWF formulations for extravascular administration in the treatment and prophylactic treatment of bleeding disorders |
| CA2728012C (en) | 2008-06-24 | 2017-10-31 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| PL2499165T3 (en) | 2009-11-13 | 2017-04-28 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| WO2013106787A1 (en) | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
| WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
| JP2015515482A (en) | 2012-04-24 | 2015-05-28 | ノヴォ ノルディスク アー／エス | Compounds suitable for the treatment of hemophilia |
| CN104411323A (en) * | 2012-04-24 | 2015-03-11 | 诺和诺德A/S（股份有限公司） | Pharmaceutical composition suitable for treating hemophilia |
| KR102403545B1 (en) | 2012-07-11 | 2022-05-30 | 바이오버라티브 테라퓨틱스 인크. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| ES2657291T3 (en) | 2013-04-22 | 2018-03-02 | Csl Ltd. | A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge |
| EP3008084A2 (en) * | 2013-06-12 | 2016-04-20 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| EP3152230B1 (en) | 2014-06-06 | 2019-08-07 | Octapharma AG | Preparation comprising factor viii and von willebrand factor peptides |
| US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
| US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
-
2017
- 2017-11-10 TW TW106139051A patent/TW201828974A/en unknown
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/en active Pending
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/en not_active Application Discontinuation
- 2017-11-10 ES ES17801644T patent/ES2908008T3/en active Active
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en unknown
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/en active
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017358865A1 (en) | 2019-05-09 |
| CA3043397A1 (en) | 2018-05-17 |
| US11890327B2 (en) | 2024-02-06 |
| DK3538134T3 (en) | 2022-02-07 |
| CN110381986B (en) | 2023-08-18 |
| SG11201903954WA (en) | 2019-05-30 |
| CN110381986A (en) | 2019-10-25 |
| JP2020504082A (en) | 2020-02-06 |
| WO2018087271A1 (en) | 2018-05-17 |
| EP3538134B1 (en) | 2021-12-29 |
| TW201828974A (en) | 2018-08-16 |
| US20210268071A1 (en) | 2021-09-02 |
| KR20190073576A (en) | 2019-06-26 |
| EP3538134A1 (en) | 2019-09-18 |
| ES2908008T3 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3892631T3 (en) | Fusion protein for use in the treatment of hvg disease | |
| PL3554631T3 (en) | Treating patients with ttfields with the electrode positions optimized using deformable templates | |
| SG10201912768YA (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| HK1254280A1 (en) | Molecular constructs for preventing the formation of blood clot and/or treating thrombosis | |
| BR112017011722A2 (en) | activin-actrii antagonists and uses for treating anemia | |
| DK3197472T3 (en) | RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI | |
| RS64556B1 (en) | Novel polypeptides and medical uses thereof | |
| HK1248714A1 (en) | Mutated fragments of the ras protein | |
| HK1250625A1 (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| IL257173A (en) | Novel insulin derivatives and the medical uses hereof | |
| IL269853A (en) | Proteins for the treatment of epithelial barrier function disorders | |
| DE112017006267A5 (en) | CONTROL DEVICE FOR AN IMPLANTABLE HEART PUMP WITH TWO IMPLANTABLE CONTROL UNITS AND WITH A CONNECTABLE SWITCH CONNECTED TO THEM | |
| IL262752B (en) | Construction of engineering bacteria for high expression of recombinant human serum albumin | |
| EP3229859B8 (en) | Dialysis machine for monitoring the time changes of the hematocrit and/or hemoglobin value | |
| EP3256158A4 (en) | Tolerance therapeutic for treating polypeptide induced allergy | |
| IL249294A0 (en) | Preparation comprising factor viii and von willebrand factor peptides | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| SG10201912360SA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| MA50358A (en) | SEMAGLUTIDE IN MEDICAL THERAPY | |
| DK3641795T3 (en) | METHODS AND MATERIALS FOR TREATING BLOOD VESSELS | |
| MX2016003871A (en) | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins. | |
| PL3648788T3 (en) | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf | |
| SG11201703624PA (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers | |
| HUE046299T2 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis |